AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.
Clinical trial NCT07208539 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07208539
- Sponsor
- Shanghai Zhongshan Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-10
- Primary completion
- 2026-04-09
- Enrollment
- 77
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.